Compare Stocks: SNTI, INMB, MGX, and FLNA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FLNA Cassava Sciences	$1.01 +5.2%	$1.21	$0.86 ▼ $4.98	$46.38M	-0.73	333,839 shs	333,244 shs
INMB INmune Bio	$1.75 -1.1%	$1.58	$1.09 ▼ $2.96	$47.06M	0.97	650,969 shs	225,746 shs
MGX Metagenomi	$1.19 -2.5%	$1.25	$1.13 ▼ $3.95	$45.93M	0.69	178,051 shs	135,771 shs
SNTI Senti Biosciences	$0.34 -5.5%	$0.85	$0.34 ▼ $2.88	$11.23M	2.04	380,546 shs	148,786 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FLNA Cassava Sciences	+5.21%	+13.37%	-19.20%	-33.11%	-53.24%
INMB INmune Bio	-1.13%	+8.02%	+4.17%	+15.89%	-34.70%
MGX Metagenomi	-2.46%	-1.24%	-1.65%	-14.39%	-47.58%
SNTI Senti Biosciences	-5.52%	-15.68%	-67.88%	-66.62%	-81.08%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FLNA Cassava Sciences	$1.01 +5.2%	$1.21	$0.86 ▼ $4.98	$46.38M	-0.73	333,839 shs	333,244 shs
INMB INmune Bio	$1.75 -1.1%	$1.58	$1.09 ▼ $2.96	$47.06M	0.97	650,969 shs	225,746 shs
MGX Metagenomi	$1.19 -2.5%	$1.25	$1.13 ▼ $3.95	$45.93M	0.69	178,051 shs	135,771 shs
SNTI Senti Biosciences	$0.34 -5.5%	$0.85	$0.34 ▼ $2.88	$11.23M	2.04	380,546 shs	148,786 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FLNA Cassava Sciences	+5.21%	+13.37%	-19.20%	-33.11%	-53.24%
INMB INmune Bio	-1.13%	+8.02%	+4.17%	+15.89%	-34.70%
MGX Metagenomi	-2.46%	-1.24%	-1.65%	-14.39%	-47.58%
SNTI Senti Biosciences	-5.52%	-15.68%	-67.88%	-66.62%	-81.08%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
FLNA Cassava Sciences	2.00	Hold	$5.00	395.05% Upside
INMB INmune Bio	2.50	Moderate Buy	N/A	N/A
MGX Metagenomi	2.80	Moderate Buy	$7.00	488.24% Upside
SNTI Senti Biosciences	2.75	Moderate Buy	$10.00	2,836.86% Upside

Current Analyst Ratings Breakdown

Latest SNTI, INMB, MGX, and FLNA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/23/2026	MGX Metagenomi	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/20/2026	FLNA Cassava Sciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/20/2026	INMB INmune Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/17/2026	SNTI Senti Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/8/2026	MGX Metagenomi	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/7/2026	MGX Metagenomi	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$7.00 ➝ $5.00
6/23/2026	MGX Metagenomi	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
6/11/2026	INMB INmune Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
6/8/2026	MGX Metagenomi	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
5/26/2026	FLNA Cassava Sciences	Maxim Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$5.00
5/19/2026	MGX Metagenomi	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)

(Data available from 8/1/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
FLNA Cassava Sciences	N/A	N/A	N/A	N/A	$1.32 per share	N/A
INMB INmune Bio	$50K	930.30	N/A	N/A	$0.88 per share	1.99
MGX Metagenomi	$25.21M	1.78	N/A	N/A	$4.22 per share	0.28
SNTI Senti Biosciences	$20K	530.33	N/A	N/A	$0.18 per share	1.89

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
FLNA Cassava Sciences	-$90.97M	-$0.87	N/A	N/A	N/A	N/A	-58.78%	-36.74%	N/A
INMB INmune Bio	-$45.93M	-$1.67	N/A	N/A	N/A	N/A	-103.03%	-77.66%	8/6/2026 (Estimated)
MGX Metagenomi	-$87.87M	-$2.30	N/A	N/A	N/A	-384.61%	-51.23%	-36.62%	8/11/2026 (Estimated)
SNTI Senti Biosciences	-$61.44M	-$1.92	N/A	N/A	N/A	N/A	-532.05%	-103.35%	8/6/2026 (Estimated)

Latest SNTI, INMB, MGX, and FLNA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	MGX Metagenomi	-$0.5531	N/A	N/A	N/A	$3.01 million	N/A
8/6/2026	Q2 2026	INMB INmune Bio	-$0.2067	N/A	N/A	N/A	$1.16 million	N/A
8/6/2026	Q2 2026	SNTI Senti Biosciences	-$0.33	N/A	N/A	N/A	$0.02 million	N/A
7/29/2026	Q2 2026	FLNA Cassava Sciences	N/A	-$0.18	N/A	-$0.18	N/A	N/A
5/14/2026	Q1 2026	SNTI Senti Biosciences	-$0.36	-$0.14	+$0.22	-$0.14	$0.02 million	$0.02 million
5/11/2026	Q1 2026	MGX Metagenomi	-$0.60	-$0.61	-$0.01	-$0.61	$5.90 million	$1.25 million
5/7/2026	Q1 2026	FLNA Cassava Sciences	N/A	-$0.21	N/A	-$0.21	N/A	N/A
5/7/2026	Q1 2026	INMB INmune Bio	-$0.2450	-$0.20	+$0.0450	-$0.20	$1.11 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
FLNA Cassava Sciences	N/A	N/A	N/A	N/A	N/A
INMB INmune Bio	N/A	N/A	N/A	N/A	N/A
MGX Metagenomi	N/A	N/A	N/A	N/A	N/A
SNTI Senti Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
FLNA Cassava Sciences	N/A	2.08	2.19
INMB INmune Bio	N/A	4.24	4.24
MGX Metagenomi	N/A	6.43	6.43
SNTI Senti Biosciences	N/A	1.04	1.04

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
FLNA Cassava Sciences	38.05%
INMB INmune Bio	12.72%
MGX Metagenomi	N/A
SNTI Senti Biosciences	25.70%

Insider Ownership

Company	Insider Ownership
FLNA Cassava Sciences	4.60%
INMB INmune Bio	21.40%
MGX Metagenomi	12.50%
SNTI Senti Biosciences	3.12%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
FLNA Cassava Sciences	20	48.31 million	46.09 million	Optionable
INMB INmune Bio	10	26.58 million	20.90 million	Optionable
MGX Metagenomi	236	37.65 million	32.94 million	N/A
SNTI Senti Biosciences	4	31.15 million	30.17 million	Not Optionable

SNTI, INMB, MGX, and FLNA Headlines

Recent News About These Companies

Senti Biosciences (SNTI) Projected to Announce Earnings on Thursday

July 30 at 3:41 AM | americanbankingnews.com

Senti Biosciences (NASDAQ:SNTI) Stock Price Down 3.2% - What's Next?

July 24, 2026 | americanbankingnews.com

Senti Biosciences Holdings, Inc. Announces a Strategic Transaction to Unlock Value for its Gene-Circuit-Enabled Pipeline, Including SENTI-202, and to Sharpen its Focus on Next ...

July 15, 2026 | markets.businessinsider.com

Senti Biosciences Holdings, Inc. Announces a Strategic Transaction to Unlock Value for its Gene-Circuit-Enabled Pipeline, Including SENTI-202, and to Sharpen its Focus on Next-Generation Controllable Genetic Medicines Powered by its Regulator Dial™ Technology Platform

July 15, 2026 | globenewswire.com

Senti Biosciences Faces Severe Refinancing and Liquidity Risks from Costly Note Structure

May 16, 2026 | tipranks.com

Senti Biosciences Holdings Announces Positive FDA RMAT Meeting on Registrational Clinical and CMC Strategy for SENTI-202 in Relapsed/Refractory AML, Along with Important ...

May 14, 2026 | markets.businessinsider.com $https://markets.businessinsider.com/news/stocks/senti-biosciences-holdings-announces-positive-fda-rmat-meeting-on-registrational-clinical-and-cmc-strategy-for-senti-202-in-relapsed-refractory-aml-along-with-important-efficacy-and-durability-1036155933$

Senti Biosciences Secures Up to $40 Million Financing and FDA Endorsement for SENTI-202 in Relapsed/Refractory Acute Myeloid Leukemia

May 14, 2026 | quiverquant.comQ

Senti Biosciences Holdings Reports First Quarter 2026 Financial Results and Highlights Advancement of SENTI-202 Program into Pivotal Phase

May 14, 2026 | globenewswire.com

Senti Biosciences Holdings Announces Positive FDA RMAT Meeting on Registrational Clinical and CMC Strategy for SENTI-202 in Relapsed/Refractory AML, Along with Important Efficacy and Durability Updates on the SENTI-202 Clinical Program

May 14, 2026 | globenewswire.com $https://www.globenewswire.com/news-release/2026/05/14/3294958/0/en/senti-biosciences-holdings-announces-positive-fda-rmat-meeting-on-registrational-clinical-and-cmc-strategy-for-senti-202-in-relapsed-refractory-aml-along-with-important-efficacy-an.html$

Senti Biosciences Holdings Inc.

May 13, 2026 | barrons.com

Senti Biosciences to Present on Logic-Gated Cell Therapies in Educational Session at AACR Annual Meeting 2026

April 13, 2026 | markets.businessinsider.com

Senti Biosciences to Present on Logic-Gated Cell Therapies in Educational Session at AACR Annual Meeting 2026

April 13, 2026 | globenewswire.com

Senti Biosciences Announces Publication in Cell Systems Demonstrating Advanced Logic-Gated CAR Design for Cell Therapies

April 1, 2026 | globenewswire.com

Senti Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update

March 27, 2026 | globenewswire.com

Senti Biosciences to Present Clinical and Translational Data on SENTI-202 at the 11th Annual Innate Killer Conference

March 23, 2026 | globenewswire.com

Senti Biosciences Amends Lease, Restructures GeneFab Sublease

March 19, 2026 | tipranks.com

Senti Biosciences to Present at Leerink Partners 2026 Global Healthcare Conference

March 3, 2026 | tmcnet.com

Senti Biosciences to Present at Leerink Partners 2026 Global Healthcare Conference

March 3, 2026 | globenewswire.com

Senti Biosciences to Showcase Gene Circuit Technology and Partnership Opportunities at TD Cowen Health Care Conference

February 24, 2026 | quiverquant.comQ

Senti Biosciences to Present at TD Cowen 46th Annual Health Care Conference

February 24, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SNTI, INMB, MGX, and FLNA Company Descriptions

Cassava Sciences NASDAQ:FLNA

$1.01 +0.05 (+5.21%)

As of 07/31/2026 04:00 PM Eastern

Filana Therapeutics Inc is a biotechnology company focused on developing novel, investigational therapies to modulate the filamin A protein for the treatment of central nervous system disorders, such as tuberous sclerosis complex (TSC)-related epilepsy, and other diseases associated with dysregulation or overexpression of filamin A. Its therapeutic product candidate, simufilam, is a proprietary small molecule oral treatment drug being studied for the treatment of TSC-related epilepsy.

INmune Bio NASDAQ:INMB

$1.75 -0.02 (-1.13%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$1.78 +0.03 (+1.49%)

As of 07/31/2026 07:57 PM Eastern

INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers. It also provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.

Metagenomi NASDAQ:MGX

$1.19 -0.03 (-2.46%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$1.20 +0.01 (+0.42%)

As of 07/31/2026 07:34 PM Eastern

Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.

Senti Biosciences NASDAQ:SNTI

$0.34 -0.02 (-5.52%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$0.34 +0.00 (+1.32%)

As of 07/31/2026 06:29 PM Eastern

Senti Biosciences, Inc. operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma. It also develops SENTI-401, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer/CRC cells. In addition, the company develops Tumor-Associated Antigen and Protective Antigen Paired Discovery Platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd for the clinical development of SENTI-301A to treat solid tumors. Senti Biosciences, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SNTI, INMB, MGX, and FLNA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SNTI, INMB, MGX, and FLNA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SNTI, INMB, MGX, and FLNA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SNTI, INMB, MGX, and FLNA Company Descriptions

Cassava Sciences NASDAQ:FLNA

INmune Bio NASDAQ:INMB

Metagenomi NASDAQ:MGX

Senti Biosciences NASDAQ:SNTI

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SNTI, INMB, MGX, and FLNA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SNTI, INMB, MGX, and FLNA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SNTI, INMB, MGX, and FLNA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SNTI, INMB, MGX, and FLNA Company Descriptions

Cassava Sciences NASDAQ:FLNA

INmune Bio NASDAQ:INMB

Metagenomi NASDAQ:MGX

Senti Biosciences NASDAQ:SNTI

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools